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A good response to L-dopa is a key feature of Parkinson’s disease (PD), and a poor response 
suggests an alternative diagnosis, but the extent of variation in the L-dopa response in definite PD is 
not well defined.  
Literature Review: 
A systematic review of papers reporting pathologically confirmed PD and L-dopa responsiveness, 
from 1971 to 2018, was performed using the medical subheadings ‘post-mortem’, ‘Parkinson’s 
disease’, and ‘L-dopa’, in PubMed, Embase, and LILACS databases.  
Cases: 
12 papers described 445 PD cases: 61.7% male, age at disease onset 64.0 years (SD 9.6), age at 
death 77.1 years (SD 7.2). L-dopa responsiveness was reported in 399 (89.7%), either as a graded or 
a binary response. In the 280 cases (70.2%) describing a graded response, it was excellent in 37.5%, 
good in 45.7%, moderate in 12.1%, and poor in 4.6%. In the 119 cases describing a binary response 
(29.8%), 73.1% were L-dopa responsive, and 26.9% were non-responsive. Comorbid brain pathology 
was present in 137 of 235 cases assessed, being cerebrovascular in 46.0% and Alzheimer’s in 37.2% 
of these, but its contribution to L-dopa responsiveness was unclear.  
Conclusions: 
The L-dopa motor response varies in definite PD. Explanations other than diagnostic inaccuracy 






Clinical diagnostic criteria for idiopathic Parkinson’s disease (PD) require the presence of core motor 
features, supported by an ‘excellent’ or ‘clear and dramatic’ L-dopa response [1, 2]. These criteria 
help to reduce clinical diagnostic error rates of between 5 and 25%, where idiopathic PD is not 
confirmed at autopsy [3, 4]. These observations might suggest that a less-than-excellent response to 
L-dopa is incompatible with a diagnosis of PD, and that variation in the L-dopa response in clinical 
trials is due to diagnostic error [5]. Clinically, benign disorders can be excluded by functional 
neuroimaging [5], but this does not exclude other neurodegenerative parkinsonian conditions. 
Assessing pathologically confirmed PD cases should give a clearer indication of the degree of 






Features of the L-dopa response 
445 pathologically confirmed PD patients (61.7% male) were identified, age at onset was 64.0 (SD 9.6) 
years, L-dopa treatment was started 3.1 (SD 3.6) years after diagnosis, and disease duration at death 
was 13.0 (SD 6.5) years. Age at death was 77.1 (SD 7.2) years (Tables 1 and 2). 
The L-dopa response was reported in 399 of 445 PD cases (89.7%) [1, 4, 6-15]. It was graded in 280 
cases: excellent in 105 (37.5%), good in 128 (45.7%), moderate in 34 (12.1%), and none-to-poor in 
13 (4.6%). In the remaining 119 cases, a binary response to L-dopa was reported: 87 (73.1%) of 
these were L-dopa responsive, and 32 (26.9%) were unresponsive. L-dopa doses were reported in 5 
of 12 papers, but were largely declared as ‘adequate’ (often defined as 1000mg per day), rather than 
quantified. Where quantified, the mean daily L-dopa dose was 917mg (SD 446) in 23 cases [6]. 
Motor complications (motor fluctuations and dyskinesia) 
Motor complications were reported in 148 patients in 4 papers [4, 10, 14, 15], being motor fluctuations 
in 63 cases (42.6%), and dyskinesia in 79 cases (53.4%).  
Comorbid brain pathology 
235 patients were assessed for the L-dopa motor response and comorbid brain pathology. 137 of 
these (58.3%) had additional brain pathology, most commonly cerebrovascular disease (46.0%) and 
Alzheimer’s disease (37.2%) (Table 1). Data about the L-dopa response, motor complications, and 









Following PRISMA guidelines, PubMed, Embase and LILACS (and references in identified papers) 
were searched from 1971 to March 2018, using the combined medical subheadings ‘levodopa’, 
‘Parkinson’s disease’, and ‘post-mortem’. The search was limited to humans, research articles, and 
English language. Studies had to include more than 5 pathologically confirmed PD cases, 
demographic details, and detail about the motor response to chronic L-dopa treatment. One 
researcher (VP) screened potentially eligible studies; a second researcher (DG) reviewed these; 
disagreements were resolved by consensus.  
Results 
893 studies were found, 757 full text articles were assessed, and 12 studies reporting 445 
pathologically confirmed PD cases met inclusion criteria. The pathological diagnosis was made (in all 
12 papers) by microscopic confirmation of severe depletion of pigmented neurons and Lewy body 
formation in the substantia nigra pars compacta. In addition, immunohistochemistry was reported in 7 
of 12 papers, including alpha-synuclein staining in 5 of 12. Pathological rating scales were reported in 
3 papers. Two papers [1, 10] recorded prospective clinical data; the remainder extracted data 
retrospectively from patient files. 3 studies also used standardised forms [4, 10, 12]. All studies 
reported the chronic out-patient L-dopa response. 
Clinical assessments  
Disease severity was graded by Hoehn and Yahr (H&Y) in 6 of 12 papers, and/or scored by the 
Unified PD Rating Scale (UPDRS) in 1 of 12 papers. 12 papers assessed the motor improvement on 
L-dopa [1, 4, 6-15], 4 the occurrence of motor complications, and 6 investigated comorbid pathologies. 
The degree of motor improvement with L-dopa was defined in 5 of 12 papers following UK Brain Bank 
descriptors [1, 10]. In the remaining 7 papers, the L-dopa motor response was categorised as either 






There is significant variation in the motor response to L-dopa treatment in pathologically confirmed 
cases; therefore, errors in the clinical diagnosis of PD do not fully explain this variability. A substantial 
proportion of pathologically confirmed PD cases have a response to L-dopa that is less than excellent. 
The definitions of what is ‘excellent’ regarding the motor response to L-dopa clearly influence this 
categorisation of patients, and such definitions have evolved. Prior to the MDS criteria for PD [2], the 
UK Queen Square Brain Bank criteria described an excellent response as ‘70-100%’ but this was 
subjective, by interpretation of case records [1]. This definition, and the similarly defined lesser 
degrees of response, was predominant in the papers in the current review, being applied in 70.2% of 
the 399 cases. In clinical trials, around half of PD cases have an excellent L-dopa response [5]. 
Around three-quarters of PD cases fulfilling MDS clinical diagnostic criteria (73.4% of 434) have an 
excellent L-dopa response [16]. Future pathological reports would benefit from inclusion of the more 
objective definition of an excellent response, being >30% improvement in UPDRS Part 3 [2] or 
≥24.5% improvement in the MDS UPDRS 3 [17].  
There are several potential explanations for these findings. A worse motor score in men than women 
despite higher L-dopa doses [18] may indicate a gender difference. Also, the postural instability gait 
difficulty phenotype is less therapy responsive than tremor dominant Parkinson’s [5]. However, an 
exception to this is benign tremulous PD: in pathologically confirmed cases, the L-dopa response 
during the first 8 years of treatment was definite in only 6 of 16 cases (37.5%), and 3 of 16 (18.8%) 
had no L-dopa response [19]. Slower progression in younger patients [20] may be partly due to better 
L-dopa responsiveness. Some of the variation in drug responsiveness may be due to genetic 
variations, such as in the dopamine metabolizing enzymes [21]. However, the pathological studies did 
not include demographic or genetic data to allow these factors to be examined in more detail. 
The studies in the current review largely predate developments in testing for genetic mutation and 
variation related to PD, so that data relating this to the L-dopa response was very limited. Larger 
studies of L-dopa responses in pathologically confirmed genetic cases are warranted. 
Other important variables in assessing the L-dopa response are the dose [5] and duration [1, 2] of 
treatment. A few cases in the pathological studies had low tolerability of L-dopa which was dose 
limiting, and detail regarding L-dopa doses was lacking in some studies, but the average treatment 
duration of 11 years before death was clearly adequate to assess treatment responses. 
The development of motor complications (motor fluctuations or dyskinesia) is a key feature in later 
stages of PD. Dyskinesia was present in around half of the post-mortem confirmed PD cases in this 
review, which is somewhat lower than the prevalence in clinical trials, and likely indicates under-
reporting in clinical notes [22].  
Our study had certain limitations. Although tissue diagnosis is the gold standard pathological definition 
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of PD, just over half of the studies that we included relied on dopaminergic cell loss and Lewy body 
formation in the substantia nigra, as they predated alpha-synuclein staining. Extraction of clinical 
information retrospectively may affect the interpretation of the L-dopa response, and be subject of 
bias. All of the studies reported the chronic L-dopa response, rather than the results from acute 
challenge tests. Two studies with a total of 176 cases had a partial overlap of up to 69 cases, which 
could not be unbundled accurately, and affected our results [1, 10]. One study in 23 patients had an 
older age at onset of 82.7 (SD 2.2) years, and a disease duration of 8.5 (SD 2.7) years at time of 
death, which was therefore an outlier [14].  
Conclusions 
Variation in the L-dopa response in pathologically confirmed PD indicates that diagnostic error alone 
does not explain this observation. Around 10% of pathologically confirmed PD are unresponsive to L-
dopa treatment, and an additional 12% have a modest response. Analysis of other modifying factors 
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Table 1: Clinical and pathological features in 445 pathologically confirmed Parkinson’s disease patients  
 PD cases (n=445) Publications (n=12) 
Age at onset (years) 64.0 (9.6) 12 
Disease duration at death (years) 13.0 (6.5) 12 
Age at death (years) 77.1 (7.2) 12 
Symptom onset to starting L-dopa 
treatment (years) 
3.1 (3.6) 2 





























Dementia 51/445 (11.5%)  5 
Assessed for comorbid pathology 
 





Diffuse Lewy body disease 





























Mean age at 
PD onset, 
years (SD) 
















  64.0 (9.6) 77.1 (7.2) 13.0 (6.5) 3.1 (3.6) 
Hughes et al. 1992 [1] 76 Not stated 69 Graded H&Y 63.6 (13.3) 76.4 (10.25) 12.8 (7.0) Not stated 
Hughes et al. 1993 [10] 100 65 95 Graded H&Y, MMSE, 
DSM 3 
62.5 (9.2) 75.6 (6.7) 13.1 (6.3) 3.2 (3.7) 
Rajput et al. 1993 [15] 26 18 20 Binary H&Y, Webster 58.8 (8.8) 70.8 (8.5) 11.7 (9.3) Not stated 
De Vos et al. 1995 [7] 18 9 18 Binary H&Y, MMSE, 
DSM 3, HAM-D 
66.2 (NS) 76.3 (NS) 10.1 (NS) Not stated 
Halliday et al. 1996 [9] 11 8 6 Binary CDR 67.4 (8.7) 77.6 (5.4) 10.3 (5.7) Not stated 
Louis et al. 1997 [12] 34 22 14 Binary None 62.0 (NS) 76.0 (NS) 14.5 (NS) Not stated 
Litvan et al. 1998 [4] 11 Not stated 11 Graded None 54.4 (4.0) Not stated 15.6 (1.6) Not stated 
Joyce et al. 2002 [11] 23 15 23 Binary None 65.0 (10.9) 78.1 (6.1)  13.2 (7.9) Not stated 
Halliday et al. 2008 [8] 7 2 7 Graded H&Y, CDR 59.4 (8.6) 73.4 (9.3) 14.0 (3.4) 1.7 (0.6) 
Matsumoto et al. 2014 [13] 16 12 16 Binary None 63.6 (10.9) 72.8 (8.4) 10.2 (6.1) Not stated 
De Pablo-Fernandez et al. 
2017 [6] 
100 60 98 Graded None 63.9 (10.3) 78.5 (6.9) 14.6 (7.7) Not stated 
Rajput et al. 2017 [14] 22 9 22 Binary H&Y, 
Webster/UPDRS, 
MMSE 
82.7 (2.3) 91.2 (3.1) 8.5 (2.7) Not stated 
 
ADL, Activity of Daily Living Scale; CDR, Clinical Dementia Rating; DSM, Diagnostic and Statistical Manual of Mental Disorders; HAM-D, Hamilton Depression Rating Scales; 
H&Y, Hoehn and Yahr; MMSE, Mini Mental State Examination; PD, Parkinson’s disease; UPDRS, Unified Parkinson’s Disease Rating Scale 
 
